Last reviewed · How we verify
Neostigmine, Atropin Biotika
Neostigmine inhibits acetylcholinesterase, allowing acetylcholine to accumulate at neuromuscular junctions and enhance muscle contraction.
Neostigmine inhibits acetylcholinesterase, allowing acetylcholine to accumulate at the neuromuscular junction and enhance muscle contraction. Used for Myasthenia gravis, Reversal of neuromuscular blockade, Postoperative urinary retention.
At a glance
| Generic name | Neostigmine, Atropin Biotika |
|---|---|
| Also known as | syntostigmine, atropine |
| Sponsor | University Hospital Olomouc |
| Drug class | Cholinesterase inhibitor |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Neostigmine is a reversible cholinesterase inhibitor that prevents the breakdown of acetylcholine by blocking the enzyme acetylcholinesterase. This leads to increased acetylcholine concentration at the neuromuscular junction, enhancing parasympathomimetic effects and improving muscle strength in conditions characterized by neuromuscular dysfunction. Atropine is often co-administered to counteract the muscarinic side effects of neostigmine.
Approved indications
- Myasthenia gravis
- Postoperative ileus and urinary retention
- Reversal of neuromuscular blockade
Common side effects
- Muscle fasciculations
- Increased salivation
- Bronchospasm
- Bradycardia
- Nausea and vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neostigmine, Atropin Biotika CI brief — competitive landscape report
- Neostigmine, Atropin Biotika updates RSS · CI watch RSS
- University Hospital Olomouc portfolio CI